Cargando…

Novel breakthrough in the treatment of sphingomyelinase deficiency

Detalles Bibliográficos
Autores principales:	Sultan, Wania, Siddiqui, Tasmiyah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389466/ https://www.ncbi.nlm.nih.gov/pubmed/36799829 http://dx.doi.org/10.1097/JS9.0000000000000102

Ejemplares similares

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

SOBA (soluble oligomer binding assay): A breakthrough or the early diagnosis of Alzheimer's disease
por: Sheikh, Ayesha, et al.
Publicado: (2023)

Prevalence of Cancer in Acid Sphingomyelinase Deficiency
por: Mauhin, Wladimir, et al.
Publicado: (2021)

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
por: Hoertel, Nicolas, et al.
Publicado: (2021)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

Apoptosis and signalling in acid sphingomyelinase deficient cells
por: Sillence, Dan J
Publicado: (2001)

Acid Sphingomyelinase Deficiency Ameliorates Farber Disease
por: Beckmann, Nadine, et al.
Publicado: (2019)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Celebrating a breakthrough: the first-ever FDA-approved treatment for geographic atrophy: a correspondence
por: Khan, Abdul Moiz, et al.
Publicado: (2023)

Metallic nanoparticle-coated sutures: a breakthrough in the field of surgery
por: Khan, Abdul Moiz, et al.
Publicado: (2023)

Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective
por: Pinto, Carolina, et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
por: Brinkley-Rubinstein, Lauren, et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Immunodeficiency Should Be Excluded in Patients With Recurrent Viral Meningitis and Breakthrough COVID-19
por: Finsterer, Josef
Publicado: (2022)

Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency
por: McGovern, Margaret M., et al.
Publicado: (2017)

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)
por: Wasserstein, Melissa, et al.
Publicado: (2018)

Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency
por: Kubaski, Francyne, et al.
Publicado: (2022)

Clinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With Autoimmunity
por: Rocco, Joseph M, et al.
Publicado: (2021)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
por: van der Veldt, A.A.M., et al.
Publicado: (2023)

Identification of Novel Functional Inhibitors of Acid Sphingomyelinase
por: Kornhuber, Johannes, et al.
Publicado: (2011)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China
por: Li, Yanhua, et al.
Publicado: (2023)

Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders
por: Sankary, Kendl M., et al.
Publicado: (2021)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency
por: Keatinge, Marcus, et al.
Publicado: (2023)

Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
por: McGovern, Margaret M., et al.
Publicado: (2017)

Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France
por: Mauhin, Wladimir, et al.
Publicado: (2022)

Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency
por: Wang, Neng-Li, et al.
Publicado: (2022)

Celebrating breakthrough in dental diagnostics: FDA approval of an AI model for diagnosis of periodontal diseases: A correspondence
por: Khan, Ayesha, et al.
Publicado: (2023)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa
por: Goga, Ameena, et al.
Publicado: (2022)

Sphingomyelinases and Liver Diseases
por: Insausti-Urkia, Naroa, et al.
Publicado: (2020)

Sphingomyelinase Treatment Induces ATP-independent Endocytosis
por: Zha, Xiaohui, et al.
Publicado: (1998)

Oncolytic viruses are a recent breakthrough in oncoimmune treatment: recent insights – correspondence
por: Amin, Ruhul, et al.
Publicado: (2023)

Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency
por: Gaudioso, Ángel, et al.
Publicado: (2023)

Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination
por: Chami, Marwan, et al.
Publicado: (2017)

Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency
por: Cassiman, David, et al.
Publicado: (2019)

Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective
por: Pokrzywinski, Robin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pu6182v2vhqav4c46cjg39h6rs